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Abstract:  
Objective: Increased vascular smooth muscle cell (VSMC) migration leads to intimal 
thickening in coronary artery restenosis and vein graft failure as well as acting as a 
soil for atherosclerosis. Investigating factors involved in VSMC migration may enable 
us to reduce intimal thickening and improve patient outcomes. In this study we 
determined whether Wnt proteins regulate VSMC migration and thereby intimal 
thickening. 
Approach and Results: Wnt2 mRNA and protein expression were specifically 
increased in migrating mouse aortic VSMCs. Moreover, VSMC migration was induced 
by recombinant Wnt2 (rWnt2) in vitro. Addition of rWnt2 protein increased Wnt1-
inducible-signalling pathway protein-1 (WISP-1) mRNA by ~1.7-fold, via -
catenin/TCF signalling, while siRNA knockdown of Wnt-2 reduced WISP-1 mRNA by 
~65%. Treatment with rWISP-1, significantly increased VSMC migration by ~1.5-fold, 
while WISP-1 siRNA knockdown reduced migration by ~40%. Wnt2 and WISP-1 
effects were integrin-dependent and not additive, indicating that Wnt2 promoted 
VSMC migration via WISP-1. Additionally, Wnt2 and WISP-1 were significantly 
increased and co-located in human coronary arteries with intimal thickening. Reduced 
Wnt2 and WISP-1 levels in mouse carotid arteries from Wnt2+/- and WISP-1-/- mice, 
respectively, significantly suppressed intimal thickening in response to carotid artery 
ligation. In contrast, elevation of plasma WISP-1 via an adenovirus encoding WISP-1 
significantly increased intimal thickening by ~1.5-fold compared to mice receiving 
control virus.  
Conclusions: Upregulation of Wnt2 expression enhanced WISP-1 and promoted 
VSMC migration and thereby intimal thickening. As novel regulators of VSMC 
migration and intimal thickening, Wnt2 or WISP-1 may provide a potential therapy for 
restenosis and vein graft failure. 
 
Keywords:  
Wnt2, WISP-1/CCN4, intimal thickening, restenosis, smooth muscle cell migration. 
  
3 
 
 
Non-standard Abbreviations and Acronyms 
BrdU bromodeoxyuridine 
CABG Coronary artery bypass graft 
Fzd frizzled receptor 
LRP low density lipoprotein receptor  
PDGF platelet derived growth factor 
Q-PCR quantitative PCR 
SFM serum free medium 
SiRNA silencing RNA 
VSMC vascular smooth muscle cell 
WISP-1 Wnt-1 inducible signalling pathway protein 1 
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Introduction 
Elevated rates of vascular smooth muscle cell (VSMC) migration and proliferation 
contribute to intimal thickening in vivo 1. Intimal thickening underlies complications 
such as restenosis following angioplasty and stent implantation and late failure of vein 
grafts 2 and acts as the soil for atherosclerosis 3. VSMC migration into the intima is a 
key process in intimal thickening since if VSMCs do not enter the intima there is no 
opportunity for accelerated VSMC proliferation within the intima. Currently, many 
approaches designed to reduce intimal thickening aim to retard VSMC proliferation, 
but anti-migratory approaches may be equally desirable.  
The Wnt signalling pathway has been implicated in intimal thickening and VSMC 
migration and proliferation by both our own group 4-6 and others 7-10. Abnormal 
upregulation of the Wnt pathway in various disease states mimics the classic role of 
the Wnt pathway during embryonic development, where the pathway controls cell 
migration and proliferation during the formation of tissues and organs 11. The Wnt 
family consists of 19 highly conserved genes that encode secreted glycoproteins 
involved in cell signalling. The Wnt ligands bind to Frizzled (Fzd) receptors and their 
co-receptors the LDL related proteins 5/6 (LRP5/6) to activate downstream pathways 
12. Upregulation of the Wnt pathway has been well established in many cancer 
subtypes 13 and in the development of osteoarthritis 14, however their role in 
atherosclerosis and restenosis is less well established. Evidence shows that the Wnt 
pathway, via the receptor LRP6, regulates cell proliferation and survival in VSMCs 7, 
while a Wnt pathway antagonist reduced proliferation 15. We previously demonstrated 
that Wnt4 directly induced VSMC proliferation, and caused intimal thickening in vivo, 
via Fzd1 activation and cyclin D1 upregulation 5. Additionally in this study we 
demonstrated that although Wnt2 mRNA was significantly elevated in proliferating 
VSMCs, this was not translated into protein and recombinant Wnt2 protein did not 
increase VSMC proliferation in vitro 5. The Wnt pathway has also been shown to have 
a role in cell migration, with Wnt3a involvement in both migration and adhesion of 
VSMCs through ILK regulation of 1-integrin 10. However, on initiation of this study it 
was unclear which Wnt proteins modulated VSMC growth factor induced migration; 
and whether Wnt-induced VSMC migration promoted intimal thickening in vivo. Many 
genes are upregulated by the Wnt pathway, some of which are known to modulate 
VSMC migration, including Wnt-1 inducible signalling pathway protein-1 (WISP-
1/CCN4) 16. WISP-1 is a member of the CCN family of genes 17 which regulates fibrosis 
and wound healing 18, angiogenesis 19, osteogenesis 20 and cancer 21. In cultured 
VSMCs WISP-1 promotes survival 19, proliferation 22, and migration through integrin 
51 23. 
In this study we aimed to identify whether any of the 19 Wnts are involved in VSMC 
migration in vitro and thereby intimal thickening in vivo. In addition, if a candidate was 
confirmed, to investigate the downstream Wnt pathway targets that promote VSMC 
migration in vitro and intimal thickening in vivo. 
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Materials and Methods 
Materials and Methods are available in the online-only Data supplement. 
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Results 
Wnt2 was upregulated in migrating VSMCs in vitro  
Wnt mRNA levels during VSMC migration were assessed using an in vitro scratch 
wound assay with multiple wounds to stimulate migration of the VSMCs. mRNA was 
extracted from VSMCs and applied to a focussed Wnt pathway microarray to assess 
whether the level of expression changed during migration. A significant increase was 
only observed in Wnt2 mRNA (Figure 1A) and this change was confirmed using Q-
PCR (Figure 1A). No significant change was seen the mRNA levels of any other Wnts 
(see Supplementary Table III). It was observed by Western blotting (Figure 1B) and 
immunocytochemistry (Supplementary Figure I) that the increase in Wnt2 mRNA was 
translated into augmented Wnt2 protein levels in migrating VSMCs. Migrating VSMCs 
on the wound edge could be seen to express higher levels of Wnt2 protein than non-
migratory VSMCs further away from the wound edge (Supplementary Figure 1). 
 
Wnt2 promoted VSMC migration in vitro 
Addition of rWnt2 protein significantly increased VSMC migration in vitro, while 
knockdown of Wnt2 using siRNA inhibited migration (Figure 1C). When rWnt2 was 
added back to VSMCs subjected to Wnt2 knockdown the inhibitory effect of Wnt2 
siRNA was reversed (Figure 1C). Recombinant Wnt2 also increased migration in the 
transwell assay (92.8±10.4 cells vs. 47.3±5.8 in control, n=4, P<0.05 student t-test). 
We previously showed that Fzds 1 and 6 are the predominant Fzds expressed in 
VSMCs 5. Knockdown of Fzd6 using siRNA resulted in a significant reduction in 
migration, while Fzd1 knockdown had no significant effect on migration (Figure 1D). 
 
Wnt2 was upregulated during intimal thickening 
To corroborate these in vitro changes in a relevant in vivo model of intimal thickening, 
mice were subjected to left carotid artery ligation. Carotids were removed after 28 days 
and stained for the presence of Wnt2 using immunofluorescence (Figure 2A-C). 
Elevated levels of Wnt2 protein were detected in the media and the intima of ligated 
carotids compared to the unligated control arteries (autofluorescence from red blood 
cells was observed in the non-immune immunoglobulin negative controls and was 
excluded from analysis of Wnt2, only intimal fluorescence and not luminal 
fluorescence was measured). 
 
Wnt2 promoted intimal thickening in vivo 
In order to determine whether Wnt2 regulated intimal thickening in vivo, Wnt2+/- mice 
were subjected to left carotid artery ligation. In unligated carotid arteries Wnt2 protein 
was undetectable in both the Wnt2+/- and Wnt2+/+ mice (Supplementary Figure IIA and 
B). Following carotid ligation we observed reduced levels of Wnt2 protein in the ligated 
arteries of Wnt2+/- mice using immunofluorescence on the carotid arteries 
(Supplementary Figure IIC), compared to ligated arteries of control wild type 
(Supplementary Figure IID), the amount of staining was quantified, showing that the 
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amount of Wnt2 protein within the intima was significantly reduced after 3 and 28 days 
of carotid ligation (Supplementary Figure IIE and F). This reduction in Wnt2 was 
associated with attenuated intimal thickening in the Wnt2+/- mice (Figure 2D). No 
significant difference was observed in the percentage of proliferating cells (measured 
using BrdU staining) at either 3 or 28 days (Supplementary Figure III) in either the 
intima (A) or the media (B).  
 
Wnt2 affected WISP-1 levels, both in vitro and in vivo 
Treatment of VSMCs with rWnt2 induced WISP-1 mRNA, while Wnt2 knockdown 
using siRNA resulted in a down-regulation of WISP-1 mRNA quantified with Q-PCR 
(Figure 3A). However, treatment of VSMCs with rWnt4 did not induce WISP-1 mRNA 
(1±) vs. 0.93±0.05). Treatment with rWnt2 caused no significant change in any other 
downstream Wnt/-catenin downstream targets that we analysed (see Supplementary 
Table IV). Induction of WISP-1 by Wnt2 treatment was inhibited using the -catenin 
inhibitor CCT03134-hydrobromide (Figure 3B). Knockdown of WISP-1 led to a 
significant reduction in migration in vitro, which was of a similar extent to that seen 
with knockdown of Wnt2 (Figure 3C). Simultaneous knockdown of both Wnt2 and 
WISP-1 did not produce an additive effect, suggesting that WISP-1 and Wnt2 are 
working in series rather than in parallel, with most likely WISP-1 downstream of Wnt2. 
Levels of Wnt2 and WISP-1 also appeared to be related in vivo, where levels of WISP-
1 were significantly reduced in the intimal lesions of Wnt2+/- mice compared to the wild 
type controls (Figure 3D). 
 
Wnt2 induced WISP-1 via -catenin 
Migration of cells in response to rWnt2, but not rWISP-1, was inhibited by the -catenin 
inhibitor, CCT03134-hydrobromide, (Figure 3E and F). This indicated that Wnt2 acts 
via -catenin in migrating cells but that WISP-1-induced migration is -catenin-
independent. 
 
Wnt2 and WISP-1 both required integrins 
Cell migration in response to both rWnt2 (Figure 3E) and rWISP-1 (Figure 3F) and 
wounding were both inhibited by the integrin inhibitor, RGD peptide, but not by a 
control peptide, suggesting that integrins are downstream of both Wnt2 and WISP-1.  
 
Wnt2 and WISP-1 co-located within intimal thickenings 
To investigate the association of Wnt2 with WISP-1, we examined whether these 
proteins were co-located in mouse ligated carotid arteries (Figure 4A-D and 
Supplementary Figure V) and early neointimal thickenings (without foam cells and 
plaque formation) in human coronary arteries (Figure 4E-F) by staining for Wnt2 and 
WISP-1 using immunofluorescence. We observed that Wnt2 and WISP-1 proteins 
were indeed co-located in both mouse and human arteries during intimal thickening. 
In human coronary arteries the amount of Wnt2 and WISP-1 proteins were significantly 
higher in arteries with early intimal thickenings compared to normal control undiseased 
arteries (Figure 4G). In addition, there was a significant correlation between the 
amount of Wnt2 and WISP-1 proteins in the vessels (r=0.647, r2 0.419, n=13, p<0.05, 
p<0.02). There was no significant difference in expression of either Wnt2 or WISP-1 
between the intima and the media. 
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WISP-1 promoted intimal thickening in vivo 
Deficiency of the WISP-1 gene produced a significant reduction in the intima formation 
(Figure 5A). In contrast, using an adenovirus encoding WISP-1 protein we increased 
plasma levels of WISP-1 protein at 3 and 7 days post-infection (Supplementary Figure 
IV) and this resulted in a significant increase in intimal formation in the carotid artery 
following ligation (Figure 5B). This confirmed that WISP-1 promoted intimal thickening 
in the mouse in vivo. Sections were stained with ISEL to identify apoptotic cells. Half 
of all sections examined had no apoptosis, while others had one or two apoptotic cells. 
No significant difference in apoptosis rates between the control and WISP-1 deficient 
mice (data not shown). The percentage of proliferating cells (measured by PCNA) was 
significantly reduced in the vessels of WISP-1 deficient animals compared to the 
wildtype controls in both the media and the intima of the vessels (Figure 5C). 
 
Discussion 
This study demonstrates that Wnt2 and WISP-1 are upregulated in migrating VSMCs 
in vitro and in intimal cells in vivo. We have also shown that modulating the levels of 
either Wnt2 or WISP-1 directly affects VSMC migration in vitro and intimal thickening 
in vivo. We have shown that Wnt2 upregulates WISP-1 and promotes VSMC 
migration, via -catenin dependent signalling. Additionally, we demonstrated that 
WISP-1 and Wnt2 promote VSMC migration via interaction with integrins. 
Consequently we suggest Wnt2 and WISP-1 are novel regulators of intimal thickening 
and thereby potential targets for reducing intimal thickening in patients following 
coronary artery bypass grafts (CABG) and stent implantation.  
Although this is the first study to demonstrate the involvement of Wnt2 in adult VSMC 
migration and intimal thickening in vivo, Wnt2 does have a well characterised role in 
cell migration in other scenarios such as during embryonic development, for example 
mouse embryo VSMCs also express Wnt2 as they migrate to form the heart, 
vasculature and lungs 24. Wnt2 also has a role in cell migration in various cancers. 
Wnt2 levels were linked to metastasis in pancreatic cancer 25, while inhibition of Wnt2 
in mouse non-small cell lung cancer cells resulted in reduced tumour cell growth 26. In 
scleroderma patients Wnt2 was found to be elevated and associated with activation of 
-catenin 27, as we have shown in our study. Therefore it is possible that the disease 
states of intimal thickening or cancers lead to a reawakening of this embryonic 
pathway, which is usually quiescent in mature cells, leading to Wnt2-dependent 
migration of cells.  
Other members of the Wnt family have also been implicated in intimal thickening, both 
by our own group and others. For example Wu et al. 10 reported that Wnt3a stimulated 
migration, adhesion and proliferation of rat VSMCs in culture. Previous work in our 
group using a similar approach to this study showed that Wnt4 was increased during 
VSMC proliferation and that modulation of Wnt4 led to changes in cell proliferation and 
intimal thickening 5. Moreover, we demonstrated that although Wnt2 mRNA, as well 
as Wnt4 mRNA, was increased in proliferating cells, this only translated into an 
increase in protein expression for Wnt4, and not for Wnt2. We also tested addition of 
both recombinant Wnt2 and Wnt4 proteins to VSMCs in culture, to assess whether 
they could directly affect proliferation. We observed that only Wnt4 induced VSMC 
proliferation and Wnt2 had no significant effect on proliferation. Additionally in our 
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previous study, we demonstrated that Wnt4 protein levels were induced during intimal 
thickening in vivo and intimal thickening induced by carotid artery ligation was 
significantly reduced in Wnt4+/- mice. A comparison of these two studies in our group 
is summarised in Figure 6 and suggests that regulation of VSMC migration and 
proliferation via -catenin dependant signalling, are controlled by different Wnt protein 
members, with Wnt2 controlling migration predominantly via Fzd 6 (although the 
involvement of Fzd 1 cannot be ruled out), and Wnt4 promoting proliferation via Fzd1.  
We investigated the mechanism of action, and discovered that Wnt2 promoted 
migration via the -catenin-dependent canonical signalling pathway, which increased 
WISP-1 levels. Knockdown of either Wnt2 or WISP-1 in vitro using siRNA resulted in 
a similar reduction in cell migration. However when both were added, this offered no 
increase in effect. This suggested that they were acting in series rather than in parallel. 
To investigate this further we looked at the effect of adding recombinant Wnt2 and 
found that this significantly increased the levels of WISP-1 in vitro, in contrast to Wnt4 
which did not affect WISP-1 levels. We also showed that WISP-1 was reduced in Wnt2 
knockout mouse ligated carotids in vivo. This shows that WISP-1 can be regulated 
directly by Wnt2 and so WISP-1 is most likely to be downstream of Wnt2. Wnt2 and 
WISP-1 were also found to be co-located in ligated mouse carotid arteries, confirming 
that activation of WISP-1 by Wnt2 is physiologically relevant as WISP-1 is found 
alongside Wnt2. 
WISP-1 has been shown previously by our own group 19 to be important in VSMC 
survival and by Liu et al. 23 to promote both VSMC migration and proliferation in 
cultured rat VSMCs. Marchand et al. confirmed the presence of WISP-1 in human 
mammary arterial cells 28, while Reddy et al. 22 showed than in human VSMCs IL-18 
increased survival and proliferation, via TCF/LEF and WISP-1. WISP-1 then acted via 
AP-1 to upregulate MMP2, 9 and 14 mRNA. Our study therefore corroborates the 
findings of Liu and colleagues 23, showing similar mechanisms in both rat and mouse 
VSMCs in culture, however we do not see the upregulation of MMP2, 9 and 14 by 
WISP-1. This is the first study to show that WISP-1 leads to intimal thickening in vivo 
and the first to examine the mechanism of action. The interplay between Wnt5a and 
Wnt2, which are both able to act via -catenin to activate WISP-1 (Figure 6) reveals 
the complexity of how various Wnts may act synergistically by overlapping pathways 
to produce different effects. More work is needed in this area to define exactly how 
these pathways may act either separately or together in different disease models. 
As with Wnt2, WISP-1 has been studied in cancer cells, where it has been shown to 
be a chemoattractant 20, encourage metastasis 29, increase invasiveness and 
decrease chances of survival 30-32. WISP-1 has also been shown in human cancer 
cells to be upregulated compared to healthy cells 33 and to stimulate migration via 
NFB activation of MMP2. Our study shows that Wnt2 acts via -catenin to upregulate 
WISP-1, which then acts through integrins to increase cell migration. This confirms 
that a similar pathway is utilised by WISP-1 in VSMCs as in other cell types. For 
example, in human oral squamous cell carcinoma cells WISP-1 acts through AP-1 and 
the v3 integrin receptor 30, while in osteogenesis WISP-1 acts via 51 integrin 20.  
To establish whether this Wnt2-WISP-1 association was present in human intimal 
lesions as well as in mice, we stained sections from human coronary arteries with early 
stage intimal thickening (without atherosclerotic plaques) to locate Wnt2 and WISP-1. 
We found that Wnt2 and WISP-1 was co-located and increased in diseased coronary 
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vessels compared to control vessels and the increase in the levels of Wnt2 and WISP-
1 in diseased vessels were correlated. This suggested that as Wnt2 increased, this 
led to an associated increase in WISP-1 as we observed in vitro.  
In summary, we have found that Wnt2 is upregulated in migrating cells both in vitro 
and in vivo and that Wnt2 promoted VSMC migration in vitro and intimal thickening in 
vivo. We identified that downstream, Wnt2 activates -catenin, leading to an 
upregulation of WISP-1; which like Wnt2, also has the ability to stimulate migration of 
cells in vitro and intimal thickening in vivo, via integrins. Although both Wnt2 and WISP-
1 have both been separately implicated to be involved in cell migration in other cell 
types, the action of Wnt2 promoting migration via WISP-1 had not been previously 
reported. WISP-1 may provide a more suitable target for drug intervention compared 
to Wnt2 as the effects may be more specific further downstream in the pathway and 
as we have shown WISP-1 promotes both migration and proliferation in this model, so 
could be a preferable candidate. However, as noted previously, WISP-1 effects other 
cell types; so ideally a tissue targeted WISP-1 inhibitor would be preferable, such as 
stent-coating or ex vivo vein graft application prior to bypass surgery. Targeting 
migration and proliferation of VSMCs from the media of the vessel into the intima 
should retard the formation of a neointima after therapies such as CABG and stent 
implantation and therefore increase the longevity of these treatments. 
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 Wnt2 is upregulated in migrating cells and promoted VSMC migration in vitro, 
and intimal thickening in vivo. 
 Wnt2 induced migration is dependent on -catenin activation, leading to an 
upregulation of WISP-1, which in turn promoted VSMC migration via integrins. 
 WISP-1 promoted intimal thickening in vivo.  
 This is the first demonstration that Wnt2 promoted migration via WISP-1. 
 WISP-1 may be a suitable target for reducing intimal thickening after therapies 
such as CABG and stent implantation and therefore increase the longevity of 
these treatments. 
 
Figure Legends 
Figure 1: Wnt2 was upregulated in migrating smooth muscle cells in vitro.  
Wnt2 mRNA was quantified by oligonucleotide array, n=3 and quantitative PCR (Q-PCR), 
n=6 (A). Data was normalised with standard housekeeping genes for the array and with 18S 
for Q-PCR and then expressed as a fold change from control (unwounded/non-migratory). * 
indicates a significant difference from control, p<0.05, one-sample t-test. (B) Western 
blotting for Wnt2 protein in control (C) and migrating (wounded, W) smooth muscle cells 
normalised with b-actin. * indicates a significant difference from control, p<0.05, one-sample 
t-test, n=4. (C) Wounded VSMCs were treated with recombinant Wnt2 protein or subjected 
to Wnt2 silencing with siRNA (Si) and the distance migrated measured. Controls were 
treated with Allstars siRNA controls. * indicates a significant difference from control, p<0.05, 
ANOVA and Student Newman Keul’s post-test, n=4. (D) Wnt2-induced migration of cells 
subjected to siRNA for Frizzled 1 and 6, expressed as a % of the Allstars siRNA control, * 
indicates a significant difference from control, p<0.05, one-sample t-test, n=3. 
 
Figure 2: Wnt2 promoted intimal thickening.  
Immunofluorescence for Wnt2 protein in carotid arteries 28 days after ligation and control 
unligated control arteries.  (A) Ligated left carotid artery with intimal thickening at 28 days 
after ligation. (B) Unligated control carotid artery. (C) Non-immune IgG negative control 
(ligated artery). Wnt2 protein (green), nuclei blue (DAPI). Red dotted line indicates the 
intimal:medial boundary. (D) Intima area in wild type (Wnt2+/+) and Wnt2 heterozygous 
knockout mice (Wnt2+/-), * indicates p<0.05, t-test n=14 per group. Images are EVG staining 
for elastin in longitudinal sections. Scale bar represents 50 m in A, B and C and 100 m in 
D.  
 
Figure 3: WISP-1 was induced by Wnt2 and WISP-1 promoted cell migration.  
(A) Relative expression of WISP-1 mRNA in VSMCs with and without Wnt2 protein 
treatment, n=4 and after silencing of Wnt2 with siRNA (Si), n=5. (B) WISP-1 mRNA following 
treatment with rWnt2 and CCT, n=3. (C) Migration of VSMCs after silencing Wnt2 and/or 
WISP-1 using scratch wound assay, n=5. (D) The percentage of WISP-1 positive intimal 
cells in wild type (Wnt2+/+) and Wnt2+/- mouse carotid arteries 28 days after ligation, n=7. 
Migration of cells following treatment with either rWnt2 (E) or rWISP-1 (F), with or without 
14 
 
CCT or RGD peptide or control  peptide, n=4.  * indicates significant difference vs. control 
P<0.05 $ indicates significant difference from rWnt2/rWISP-1 treatment, using either t-test or 
ANOVA as applicable.  
 
Figure 4: Colocation of Wnt2 and WISP-1 in mouse intimal lesions and human 
coronary artery disease. 
Immunofluorescence for Wnt2 (A: green) and WISP-1 (B: red) proteins and merged images  
(C: yellow). Non-immune IgG negative control (D). White dotted line indicates the 
intima:media boundary. Scale bar in (A) represents 50 µm and applies to panels A-D. 
Human early coronary lesions were subjected to immunofluorescence for Wnt2 protein (E: 
green) and WISP-1 protein (F: red), nuclei are blue (DAPI) in human coronary artery with 
intima. Scale bar in (E) represents 50 m and applies to panels E and F. Quantification of 
intimal and medial Wnt2 and WISP-1 proteins in control undiseased coronary arteries and 
coronary arteries with early intimal thickening (G). * indicates significant difference from 
controls (ANOVA and Kruskal Wallis post test, n=5 controls, n=5 with intimal thickening, 
p<0.05).  
 
Figure 5: WISP-1 promoted intimal thickening.  
(A) Intima area within carotid arteries 28 days after ligation in wild type controls and  
WISP-1-/- mice, n=12. (B) Intima area within carotid arteries 28 days after ligation in mice 
infected with control adenovirus and adenovirus to overexpress WISP-1, n=10. Scale bars 
represents 100 m. * indicates significant difference vs. control P<0.05. (C) Percentage of 
proliferating cells in the intima and media measured by PCNA staining * indicates significant 
difference vs. control P<0.05.  
 
Figure 6: Summary of the roles of Wnt2, Wnt4 and Wnt5a in the regulation of VSMC 
behaviour.  
Arterial injury leads to the increased expression of Wnts 2 and 4. Wnt2 activates-
catenin/TCF signalling predominantly via Fzd6, leading to the induction of WISP-1 which 
promotes VSMC migration via integrins. Wnt4 activates -catenin/TCF signalling via Fzd1, 
leading to the induction of cyclin D1 which promotes VSMC proliferation. In the presence of 
oxidative stress Wnt5a activates -catenin/CREB signalling, leading to the induction of 
WISP-1 which promotes VSMC survival, whether this is via integrins is unknown. 
Summarised from data within this paper as well as previous work by Tsaousi et al and Mill et 
al [5 & 19].
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Materials and Methods 
Animals 
The housing and care of all the animals and the procedures used in these studies 
were performed in accordance with the guidelines and regulations of the University of 
Bristol and the United Kingdom Home Office. The investigation conforms to the Guide 
for the Care and Use of Laboratory Animals published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996). 
Transgenic mice. Wnt2 heterozygous knockout mice (Wnt2+/-) on a pure CD-1 
background from more than 10 backcrosses, were kindly provided by Dr Richard Lang 
(Cincinnati Children’s Hospital, Cincinnati, OH). WISP-1 homozygous knockout mice 
(WISP-1-/-) on a pure C57/bl6J background from more than 10 backcrosses, were 
kindly provided by Dr Marian Young (NIH, Bethesda, Maryland). Mice were bred within 
the University of Bristol animal unit to provide sufficient numbers of male Wnt2+/- or 
WISP-1-/- mice and their wild type littermate controls (Wnt2+/+ or WISP-1+/+). 
Homozygous Wnt2-/- animals could not be used as a result of perinatal death due to 
placental defects 1. 
Elevation of plasma WISP-1. To overexpress WISP-1, 30 mice were anaesthetised 
using inhaled isoflurane and warmed on a heated plate, to increase the prominence 
of the tail vein, before receiving a tail vein injection of RAd66 empty virus (8 x 1010 
particles/mouse1.1 x 109 pfu/mouse) as previously described 2-4. Mice were allowed 
to recover on a heat mat before returning them to their cage. Four hours later the 
procedure was repeated and mice were given a further injection of either RAd66 or 
RAdWISP-1 (15 mice in each group, 2.2 x 108 pfu/mouse). The RAdWISP-1 encoding 
virus was kindly supplied by Marian Young and was previously described 5. 
Carotid ligation. Left carotid artery ligations were performed to induce intimal 
thickening, as described previously 6. Thirty mice were anaesthetised using inhaled 
isoflurane with oxygen and intraperitoneal injection of buprenorphine hydrochloride 
(1.5g) and prepared for sterile surgery. The left common carotid artery was dissected 
and ligated just proximal to the carotid bifurcation to induce intimal formation. Mice 
also received an implanted minipump (Alzet 2004) in the subcutaneous space on their 
back containing BrdU (25mg/ml) to enable identification of proliferating cells. 
Histochemistry, Immunohistochemistry and Immunofluorescence 
Carotid arteries were removed either 3 or 21 days following ligation surgery, formalin 
fixed for 24 hours and embedded longitudinally or transversely in agar before 
processing and embedding in paraffin wax. 3 m sections were cut onto Superfrost 
slides for elastin van Gieson (EVG) staining and on to Superfrost Plus slides for 
immunohistochemistry and immunofluorescence. EVG stained sections were used for 
visualisation and measurement of the vessel and lesion by image analysis (Image 
Pro). Immunohistochemistry was performed to visualise BrdU incorporation (Sigma: 
B2531; 8.6g/ml) and PCNA staining (Abcam 18197; 1g/ml); and 
immunofluorescence was utilised to localise Wnt2 (Santa Cruz: SC5208; 1.25g/ml), 
WISP-1 (R&D: AF1680; 1g/ml), and cleaved caspase 3 (R&D Systems: MAB835; 
10g/ml). Non-immune IgG of the same species as the primary was used as negative 
control in all protocols at the same concentration as the primary antibody to 
demonstrate the specificity of the protocol. Apoptosis was measured using ISEL as 
described previously 7. 
Tissue culture and in vitro migration assays 
Primary cultured VSMCs were obtained by culturing explants from aortae from C57/bl6 
mice as described previously 6. Cells were used from passage 3-9 and at least 3 
different preparations were used for each experiment. VSMCs were quiesced for 24 
hours at 37oC and 5% CO2 in serum free medium (SFM) before either treatment with 
500ng/ml recombinant Wnt2 or being subjected to either a single or multiple scratch 
wound assay as described previously 8, in SFM supplemented with 20ng/ml PDGF 
and 2M hydroxyurea (to inhibit proliferation). To quantify migration, VSMCs were 
grown in a 24 well plate and subjected to two perpendicular wounds to form a cross. 
Wells were photographed immediately following wounding and then again 24 hours 
after wounding to measure the distance migrated by the VSMCs. For measurement of 
mRNA or protein, VSMCs were cultured in a 6 well plate and subjected to 20 wounds 
in two directions to form a grid pattern. VSMCs were left to migrate for either 6 hours 
(for mRNA) or 24 hours (for protein) before lysing the VSMCs in the relevant lysis 
buffer. In some experiments VSMCs were cultured in the presence of 500 ng/ml 
recombinant Wnt2, or recombinant WISP-1 and the inhibitors CCT03134-
hydrobromide (Tocris, 20nM) and RGD peptide (Peptides International, 250M) were 
also added. Cells were also seeded into a transwell cell culture inserts with 8m pores 
(Millipore) and the number of VSMCs that migrated across the membrane in response 
to Wnt2 after 24 hours was measured as previously described 8. 
RNA extraction and reverse transcription 
RNA was extracted from VSMCs using the RNAeasy kit (Qiagen) according to the 
manufacturer’s instructions. RNA was then processed for Q-PCR analysis using 
reverse transcription using the RT-PCR Kit (Qiagen) or for focussed microarray 
analysis as described below. 
Focussed Microarray Analysis 
RNA was directly labelled with Biotin-UTP (Roche) and amplified using the TrueLabel 
AMP 2.0 Kit (SuperArray: GA-030). The Biotin-UTP labelled RNA was cleaned using 
the RNAeasy kit (Qiagen). A mouse Wnt pathway microarray (SuperArray: OMM-043-
4) was left rotating overnight at 37oC in a hybridising oven with 1g of cleaned, purified 
and labelled mRNA in 2ml of hybridisation solution. Hybridised oligonucleotides were 
detected using an enhanced luminescence kit (SuperArray: D-01,) according to the 
instructions, after washing twice for 30 minutes with SSC containing buffers (Sigma: 
85635) at room temperature. The GEAnalysis software (SuperArray: GA-021) was 
used for quantification following normalisation using housekeeping genes and 
concentration controls (GAPDH, BAS2C, Ppia, Hspcb, B2m, Rps27a, and two blank 
controls) on the array. 
Quantitative PCR (Q-PCR) 
cDNA was subjected to Q-PCR for Wnt pathway genes using specific primers (see 
Supplementary Table I) as described previously 6. Results were normalised to 18s 
ribosomal RNA. 
 
Western Blotting 
SDS lysis buffer was used to extract VSMC proteins and total protein concentration 
was measured using a bicinchroninic acid protein assay kit (Pierce). Equal protein 
concentrations were loaded on 4-12% gradient gels (Novex Bis-Tris gel) and 
transferred on to 0.2m nitrocellulose membranes. Blots were blocked with 5% (w/v) 
skimmed milk powder and incubated overnight at 4oC with anti-Wnt2 antibody (Abcam: 
ab27794; 4g/ml) diluted in starting block (Pierce). Primary antibodies were detected 
using HRP conjugated secondary antibodies and enhanced chemiluminescence 
reagent (ECL, Amersham). Optical density of bands was quantified using densitometry 
(Quantity One) and normalised to a -actin loading control (Sigma: A5316; 110ng/ml). 
Immunocytochemistry 
Following the in vitro migration assay VSMCs were fixed in 3% (w/v) 
paraformaldehyde for 10 minutes, washed with 0.1% (v/v) triton in PBS and blocked 
with 20% (v/v) rabbit serum for 1 hour. VSMCs were then and treated with Wnt2 
antibody (Santa Cruz: SC5208; 5g/ml) or IgG used at 200 g/ml in 1% (w/v) BSA in 
PBS overnight at 4°C. The next day VSMCs were washed and treated with rabbit anti 
goat Alexa flour 488 at 1:200 for 45 minutes, wrapped in foil before washing and 
mounting with Prolong gold with 4',6-diamidino-2-phenylindole (DAPI). 
Silencing RNA (SiRNA) 
SiRNA oligonucleotides for Wnt2, WISP-1 and Frizzleds 1 and 6 (Supplementary 
Table II) were purchased from Qiagen along with Allstars scrambled negative control 
(Qiagen SI03650318) and introduced into VSMCs using an AMAXA nucleofector 
device and VSMC kit (API-1004, Lonza) according to the manufacturer’s instructions. 
VSMCs (1 x 106) were subjected to nucleofection with 250pmol of Wnt2, WISP-1, Fzds 
or Allstars control siRNAs using program A33 and analysed after 24 hours. The 
knockdown efficiency was quantified using Q-PCR of target mRNA and found to be 
significantly reduced by <50%, as previously published for Wnt2 6, WISP-1 9 and Fzds 
6. 
Statistics 
 
Results are expressed as mean+SEM. All data was checked for normal distribution 
and since this was the case for all data, they were analysed by student t-test for 
comparison of two groups, one-sample t-test for one group analyses and two-way 
ANOVA with Kruskal Wallis post-test for multiple comparisons with more than two 
groups. A significant difference was accepted when p<0.05. 
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Supplementary Figure I: 
Wnt2 was increased in migrating smooth muscle cells in vitro.
Immunofluorescence for Wnt2 protein (green) in VSMCs 24 hours after subjecting to wound injury 
(A). Red line indicates the position of the wound.
(B) Migrating cells on edge of wound, (C) Non-migratory cells, (D) Non-immune IgG negative control. 
Nuclei are blue (DAPI). Scale bar represents 200 mm in (A) and 20 µm in (B) and applies to panels 
B-D.
A B
C D
Supplementary Figure II: 
Wnt2 protein was reduced in Wnt2+/- mice.
Immunofluorescence for Wnt2 protein in control non-ligated carotid arteries (A and B) and ligated 
carotid arteries (C and D) 28 days following ligation. Wnt2+/- (A and C) and wild type mice (B and D: 
Wnt2+/+) dotted lines show the intima/media boundaries, i = intima, m = media. 
Quantification of Wnt2 protein in media of ligated carotid arteries after 3 days (E) and in intima and 
media after 28 days (F) in Wnt2+/- and control Wnt2+/+ mice, n=5, p<0.05 using t-test and Mann-
Whitney test. Scale bar = 50 mm.
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Supplementary Figure III: 
Proliferation in ligated arteries.
The percentage of proliferating cells in the intima (A)  and media (B) was quantified by BrdU
incorporation and compared in Wnt2+/+ and Wnt2+/- mice at 3 days and 28 days after ligation, n=6.
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Supplementary Figure IV: 
Treatment with WISP-1 virus increased plasma WISP-1.
Plasma WISP-1 was quantified after 3, 7 and 28 days using ELISA.  
* indicates a significant difference from control (n=4, p<0.05, Mann-Whitney test).
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Supplementary Figure V: 
Wnt2 and WISP-1 are upregulated at 7 days
Representative images of immunofluorescence for Wnt2 (A) and WISP-1 (C) proteins 
(green) in serial sections of carotid arteries 7 days after ligation. Non-immune 
immunoglobulin controls are shown in (B) and (D), respectively. Nuclei are stained blue with 
DAPI.
Gene Source Primer sequence Forward Primer sequence Reverse
Brachyury Sigma GCTTCAAGGAGCTAACTAACGAG CCAGCAAGAAAGAGTACATGGC
Frizzled 7 Sigma GTCCCACCGCCTACCCTACTG GTGAGCACCGTGAAGAGCGTC
Frizzled 10 Sigma TGGTACGCATAGGGGTCTTC TCAGGCAGTCAGGTGTCTTG
FoxN1 Sigma CACTGGAAGCCTTTGAGGAG AAGGCAGGCTGAGAAGAACA
MMP2 Sigma GGCTGACATCATGATCAACTTTGG GCCATCAGCGTTCCCATACTTTAC
MMP7 Sigma AATGGCATTCCAGAATTGTCACCT GATCTCTCCTTGCGAAGCCAATTA
MMP9 Sigma GAGAACACCACCGAGCTATCCACT AGAGAGGAGTCTGGGGTCTGGTTT
MMP14 Sigma ACCACAAGGACTTTGCCTCTGAAG CACTGAGCTGTGAGATTCCCTTGA
Porcupine Sigma TGGAGTTCATGGGCTACCTCT CGTTTCTTGTTGCGAAGGAGT
Sox17 Sigma GATGCGGGATACGCCAGTG CCACCACCTCGCCTTTCAC
Senp2 Sigma GCTGGCTAAGGTTCTCGGC CTGGGATCTCATCAGTGTCCA
WISP-1 Sigma CGTGGAGCAACGGTATGAG GAGAGTGAAGTTCGTGGCC
WISP-2 Qiagen Quantitect QT01061571 
Supplementary Tables 
Supplementary Table I: Primer sequences used for Q-PCR
Gene Source Catalogue No Catalogue No
WISP-1 (Mouse) Qiagen S100212702 S102673370
Wnt2 (mouse) Qiagen S101472653 S101472660
Frizzled 1 Qiagen S100218771 S102674252 
Frizzled 6 Qiagen S102666979 S102708510
Supplementary Table II: SiRNA probes used for knockdown of WISP-1 and Wnt2
Wnt pathway member Average fold change 
(n=3 arrays)
One sample t-test vs. 1
p value
Wnt1 2.01±0.63 NS
Wnt2 2.39±0.35 p<0.05
Wnt2b 2.36±1.09 NS
Wnt3 0.64±1.10 NS
Wnt3a 0.05±0.98 NS
Wnt4 0.45±0.54 NS
Wnt5a 0.32±0.23 NS
Wnt5b 1.20±0.78 NS
Wnt6 1.28±0.34 NS
Wnt7a 0.40±0.39 NS
Wnt7b 1.50±1.22 NS
Wnt8a 1.45±0.96 NS
Wnt8b 2.88±1.86 NS
Wnt9a not detectable
Wnt9b 5.34±3.36 NS
Wnt10a 0.12±0.55 NS
Wnt10b 1.11±0.28 NS
Wnt11 1.46±0.67 NS
Wnt16 0.96±0.42 NS
Supplementary Table III: Fold change of Wnt pathway genes quantified by microarrays.
Wnt2 downstream 
target
Average fold change ± sem 
(n=3-6)
One sample t-test vs. 1
Brachyury 1.19±0.52 NS
Frizzled 7 2.52±1.46 NS
Frizzled 10 1.25±0.60 NS
MMP2 9.79±9.47 NS
MMP7 3.43±1.75 NS
MMP9 1.35±0.52 NS
MMP14 4.45±2.20 NS
Porcupine 1.21±0.33 NS
Senp2 1.22±0.32 NS
Sox17 1.32±0.36 NS
WISP-1 1.67±0.14 *P<0.05
WISP-2 0.79±0.57 NS
Supplementary Table IV: Fold change of potential Wnt2 responsive downstream genes
following addition of recombinant Wnt2: mRNA quantified by Q-PCR.
